Nvidia’s Bold Move: Tackling Tech’s $1 Trillion Crisis

Taiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as 4,744%. Now, if you’re like everybody else, you want to know what Nvidia’s doing next … and who they’re going to partner with …

Find out details on these three critical Nvidia partners immediately.

Howard Robin Biography and Net Worth

CEO of Nektar Therapeutics

Howard W. Robin is President, Chief Executive Officer, Director of the Company. Mr. Robin served as Chief Executive Officer, President and a director of Sirna Therapeutics, Inc., a biotechnology company, from July 2001 to November 2006 and from January 2001 to June 2001, served as their Chief Operating Officer, President and as a director. From 1991 to 2001, Mr. Robin was Corporate Vice President and General Manager at Berlex Laboratories, Inc. (Berlex), a pharmaceutical products company that is a subsidiary of Schering, AG, and from 1987 to 1991 he served as Vice President of Finance and Business Development and Chief Financial Officer of Berlex. From 1984 to 1987, Mr. Robin was Director of Business Planning and Development at Berlex. He was a Senior Associate with Arthur Andersen & Co. prior to joining Berlex. Mr. Robin serves as a director of the Biotechnology Industry Organization, the world’s largest biotechnology industry trade organization, and also serves as a director of BayBio, a non-profit trade association serving the Northern California life sciences community. He received his B.S. in Accounting and Finance from Fairleigh Dickinson University in 1974.

What is Howard W. Robin's net worth?: The estimated net worth of Howard W. Robin is at least $1.11 million as of December 17th, 2024. Mr. Robin owns 1,195,710 shares of Nektar Therapeutics stock worth more than $1,109,978 as of December 21st. This net worth estimate does not reflect any other assets that Mr. Robin may own. Additionally, Mr. Robin receives a salary of $1,830,000.00 as CEO at Nektar Therapeutics. Learn More about Howard W. Robin's net worth.
How old is Howard W. Robin?: Mr. Robin is currently 71 years old. There are 4 older executives and no younger executives at Nektar Therapeutics. Learn More on Howard W. Robin's age.
What is Howard W. Robin's salary?: As the CEO of Nektar Therapeutics, Mr. Robin earns $1,830,000.00 per year. Learn More on Howard W. Robin's salary.
How do I contact Howard W. Robin?: The corporate mailing address for Mr. Robin and other Nektar Therapeutics executives is 455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO CA, 94158. Nektar Therapeutics can also be reached via phone at (415) 482-5300 and via email at [email protected]. Learn More on Howard W. Robin's contact information.
Has Howard W. Robin been buying or selling shares of Nektar Therapeutics?: During the past quarter, Howard W. Robin has sold $63,905.73 of Nektar Therapeutics stock. Most recently, Howard W. Robin sold 46,995 shares of the business's stock in a transaction on Tuesday, December 17th. The shares were sold at an average price of $1.01, for a transaction totalling $47,464.95. Following the completion of the sale, the chief executive officer now directly owns 1,195,710 shares of the company's stock, valued at $1,207,667.10. Learn More on Howard W. Robin's trading history.
Who are Nektar Therapeutics' active insiders?: Nektar Therapeutics' insider roster includes Robert Chess (Director), Myriam Curet (Director), Gil Labrucherie (CFO), John Northcott (SVP), Howard Robin (CEO), Jillian Thomsen (CAO), Mark Wilson (SVP), and Jonathan Zalevsky (Insider). Learn More on Nektar Therapeutics' active insiders.
Are insiders buying or selling shares of Nektar Therapeutics?: During the last year, insiders at the biopharmaceutical company sold shares 12 times. They sold a total of 272,472 shares worth more than $332,493.55. The most recent insider tranaction occured on December, 19th when insider Jonathan Zalevsky sold 51,115 shares worth more than $48,048.10. Insiders at Nektar Therapeutics own 3.7% of the company. Learn More about insider trades at Nektar Therapeutics.
Information on this page was last updated on 12/19/2024.

Howard W. Robin Insider Trading History at Nektar Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
12/17/2024	Sell	46,995	$1.01	$47,464.95	1,195,710
11/19/2024	Sell	16,278	$1.01	$16,440.78	832,080
8/19/2024	Sell	14,881	$1.28	$19,047.68	848,358
5/17/2024	Sell	16,650	$1.75	$29,137.50	863,239
2/20/2024	Sell	20,033	$0.68	$13,622.44	879,889
11/17/2023	Sell	19,877	$0.49	$9,739.73	899,922
8/16/2023	Sell	19,998	$0.78	$15,598.44	919,799
5/16/2023	Sell	20,361	$0.72	$14,659.92	939,797
2/16/2023	Sell	19,635	$3.00	$58,905.00	960,158
11/16/2022	Sell	38,014	$3.57	$135,709.98	979,793
8/16/2022	Sell	13,759	$4.76	$65,492.84	1,017,807
5/16/2022	Sell	36,529	$3.95	$144,289.55	620,941
2/16/2022	Sell	12,480	$10.95	$136,656.00
8/16/2021	Sell	11,515	$13.83	$159,252.45	424,123
5/17/2021	Sell	11,560	$18.30	$211,548.00	435,638
2/3/2021	Sell	150,000	$19.72	$2,958,000.00	608,693
8/17/2020	Sell	11,885	$19.67	$233,777.95	364,018
2/18/2020	Sell	8,448	$22.35	$188,812.80	384,871
11/18/2019	Sell	13,556	$17.97	$243,601.32	299,219
10/16/2019	Sell	33,334	$17.48	$582,678.32	346,108
8/16/2019	Sell	12,551	$18.15	$227,800.65	282,775
7/24/2019	Sell	33,334	$32.11	$1,070,354.74	328,659
5/23/2019	Sell	100,000	$33.00	$3,300,000.00	328,659
5/21/2019	Sell	33,333	$32.93	$1,097,655.69	328,659
5/16/2019	Sell	13,383	$31.37	$419,824.71	295,326
2/21/2019	Sell	108,882	$42.19	$4,593,731.58	350,924
2/19/2019	Sell	42,215	$42.33	$1,786,960.95	350,924
11/16/2018	Sell	15,326	$38.25	$586,219.50	249,141
6/27/2018	Sell	130,000	$49.52	$6,437,600.00	267,690
6/25/2018	Sell	43,334	$51.82	$2,245,567.88	267,690
5/16/2018	Sell	12,791	$83.39	$1,066,641.49	224,356
5/3/2018	Sell	130,000	$84.05	$10,926,500.00	280,481
5/1/2018	Sell	43,334	$83.65	$3,624,889.10	280,481
2/16/2018	Sell	12,788	$82.94	$1,060,636.72	237,147
1/22/2018	Sell	83,333	$75.82	$6,318,308.06	333,268
12/13/2017	Sell	83,333	$55.69	$4,640,814.77	272,768
11/1/2017	Sell	83,334	$23.57	$1,964,182.38	235,838
10/9/2017	Sell	83,333	$24.20	$2,016,658.60
9/6/2017	Sell	83,333	$21.54	$1,794,992.82	235,837
8/16/2017	Sell	91,714	$19.26	$1,766,411.64	152,504
5/16/2017	Sell	8,388	$19.55	$163,985.40	160,884
2/16/2017	Sell	8,636	$13.14	$113,477.04	169,272
2/8/2017	Sell	87,500	$13.04	$1,141,000.00	265,408
1/17/2017	Sell	87,500	$12.35	$1,080,625.00	265,408
11/17/2016	Sell	93,458	$13.88	$1,297,197.04	122,908
10/4/2016	Sell	87,500	$17.06	$1,492,750.00
9/1/2016	Sell	87,500	$17.83	$1,560,125.00
8/16/2016	Sell	11,817	$17.56	$207,506.52
5/17/2016	Sell	2,170	$13.58	$29,468.60	19,103
2/17/2016	Sell	2,147	$11.92	$25,592.24	13,478
2/10/2016	Sell	66,666	$11.49	$765,992.34	10,000
1/19/2016	Sell	66,667	$14.12	$941,338.04	10,000
12/3/2015	Sell	125,001	$15.87	$1,983,765.87	10,000
11/11/2015	Sell	125,000	$13.52	$1,690,000.00	10,000
10/6/2015	Sell	125,000	$10.99	$1,373,750.00	10,000
9/23/2015	Sell	124,999	$13.04	$1,629,986.96	10,000
8/13/2015	Sell	58,333	$10.89	$635,246.37
7/14/2015	Sell	58,334	$11.78	$687,174.52
12/1/2014	Sell	350,000	$17.01	$5,953,500.00
11/25/2014	Sell	600,000	$15.25	$9,150,000.00
11/24/2014	Sell	132,800	$15.02	$1,994,656.00

Howard W. Robin Buying and Selling Activity at Nektar Therapeutics

Nektar Therapeutics Company Overview

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. The company was incorporated in 1990 and is headquartered in San Francisco, California.

Today's Range

Now: $0.93

$0.90

$0.96

50 Day Range

MA: $1.19

$0.93

$1.45

2 Week Range

Now: $0.93

$0.46

$1.93

Volume

1,787,229 shs

Average Volume

1,795,548 shs

Market Capitalization

$171.23 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.57

Nvidia’s Bold Move: Tackling Tech’s $1 Trillion Crisis

From Weiss Ratings | Ad

Find out details on these three critical Nvidia partners immediately.

Howard Robin Biography and Net Worth

What is Howard W. Robin's net worth?

How old is Howard W. Robin?

What is Howard W. Robin's salary?

How do I contact Howard W. Robin?

Has Howard W. Robin been buying or selling shares of Nektar Therapeutics?

Who are Nektar Therapeutics' active insiders?

Are insiders buying or selling shares of Nektar Therapeutics?